Molecular basis of 60 years of antigenic evolution of human influenza A(H3N2) virus neuraminidase
Cell Host & Microbe · 2026-01 · 34 (1) · 103-115.e9
DOI: 10.1016/j.chom.2025.12.006 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Host & Microbe, 2026-01. Verfasst von Miruna E Rosu und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Viroscience, Erasmus University Medical Centre, Dr. Molewaterplein 40, 3015 GD Rotterdam, the Netherlands. Hauptthemen laut MEDLINE: Neuraminidase, Influenza A Virus, H3N2 Subtype, Evolution, Molecular, Antigens, Viral. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 91 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NIH HHS, Horizon 2020.
Abstract (Originalsprache)
Human influenza A viruses escape antibody-mediated immunity through changes in the hemagglutinin (HA) and neuraminidase (NA) glycoproteins. HA antigenic evolution has been studied extensively, with more recent interest in NA due to its importance in influenza vaccine efficacy. Here, the antigenic properties of the NA of more than 300 A(H3N2) and A(H2N2) viruses isolated since 1957 were quantified with a NA inhibition enzyme-linked lectin assay and visualized using antigenic cartography, with follow-up molecular studies using recombinant viruses. The antigenic evolution of N2 NA was more gradual than that described for H3 HA, and antigenic changes in NA and HA were discordant. Multiple substitutions around the NA active site and tetramer lateral side that alter the charge, volume, or hydropathy of amino acids collectively determined antigenic properties. These data facilitate sequence-based genomic surveillance and inference of antigenic phenotypes from genotypes and offer opportunities to improve influenza vaccine effectiveness through increased focus on NA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Viroscience, Erasmus University Medical Centre, Dr. Molewaterplein 40, 3015 GD Rotterdam, the Netherlands.
- Center for Pathogen Evolution, Department of Zoology, University of Cambridge, Downing St., Cambridge CB2 3EJ, UK.
- Center for Pathogen Evolution, Department of Zoology, University of Cambridge, Downing St., Cambridge CB2 3EJ, UK; Institute of Virology, Charité - Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany.
- Department of Viroscience, Erasmus University Medical Centre, Dr. Molewaterplein 40, 3015 GD Rotterdam, the Netherlands. Electronic address: r.fouchier@erasmusmc.nl.
Förderung
- NIAID NIH HHS
- NIH HHS
- Horizon 2020
- Horizon 2020 Framework Programme
- NIH NIAID
Zitieren
APA
Rosu, M. E., Westgeest, K. B., de Graaf, M., Hauser, B. M., Tureli, S., James, S., Sinartio, F. F., Bestebroer, T. M., Lexmond, P., Pronk, M. R., van der Vliet, S., Skepner, E., Spronken, M. I. J., Mühlemann, B., Richard, M., Jones, T. C., Smith, D. J., Herfst, S., & Fouchier, R. A. M. (2026). Molecular basis of 60 years of antigenic evolution of human influenza A(H3N2) virus neuraminidase. Cell Host & Microbe, 34(1), 103-115.e9. https://doi.org/10.1016/j.chom.2025.12.006
Vancouver
Rosu ME, Westgeest KB, de Graaf M, Hauser BM, Tureli S, James S, et al. Molecular basis of 60 years of antigenic evolution of human influenza A(H3N2) virus neuraminidase. Cell Host & Microbe. 2026;34(1):103-115.e9. doi:10.1016/j.chom.2025.12.006
BibTeX
@article{Rosu2026,
author = {Rosu, Miruna E and Westgeest, Kim B and de Graaf, Miranda and Hauser, Blake M and Tureli, Sina and James, Sarah and Sinartio, Felisita F and Bestebroer, Theo M and Lexmond, Pascal and Pronk, Mark R and van der Vliet, Stefan and Skepner, Eugene and Spronken, Monique I J and Mühlemann, Barbara and Richard, Mathilde and Jones, Terry C and Smith, Derek J and Herfst, Sander and Fouchier, Ron A M},
title = {Molecular basis of 60 years of antigenic evolution of human influenza A(H3N2) virus neuraminidase},
journal = {Cell Host & Microbe},
year = {2026},
volume = {34},
number = {1},
pages = {103--115.e9},
doi = {10.1016/j.chom.2025.12.006}
}
EUVIMED